|
1
|
Spiro SG and Porter JC: Lung cancer –
where are we today? Current advances in staging and nonsurgical
treatment. Am J Respir Crit Care Med. 166:1166–1196. 2002.
|
|
2
|
Kelly K, Crowley J, Bunn PA Jr, et al:
Randomized phase III trial of paclitaxel plus carboplatin versus
vinorelbine plus cisplatin in the treatment of patients with
advanced non-small cell lung cancer: a Southwest Oncology Group
trial. J Clin Oncol. 19:3210–3218. 2001.PubMed/NCBI
|
|
3
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced non-small
cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar
|
|
4
|
Ohe Y, Ohashi Y, Kubota K, et al:
Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shepherd FA, Rodrigues-Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim ES, Hirsh V, Mok T, et al: Gefitinib
versus docetaxel in previously treated non-small-cell lung cancer
(INTEREST): a randomised phase III trial. Lancet. 372:1809–1818.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takano T, Fukui T, Ohe Y, et al: EGFR
mutations predict survival benefit from gefitinib in patients with
advanced lung adenocarcinoma: a historical comparison of patients
treated before and after gefitinib approval in Japan. J Clin Oncol.
26:5589–5595. 2008. View Article : Google Scholar
|
|
12
|
Azzoli CG, Baker S Jr, Temin S, et al:
American Society of Clinical Oncology Clinical Practice Guideline
update on chemotherapy for stage IV non-small-cell lung cancer. J
Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar
|
|
13
|
Nagai Y, Miyazawa H, Huqun, et al: Genetic
heterogeneity of the epidermal growth factor receptor in non-small
cell lung cancer cell lines revealed by a rapid and sensitive
detection system, the peptide nucleic acid-locked nucleic acid PCR
clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar
|
|
14
|
Sutani A, Nagai Y, Udagawa K, et al:
Gefitinib for non-small-cell lung cancer patients with epidermal
growth factor receptor gene mutations screened by peptide nucleic
acid-locked nucleic acid PCR clamp. Br J Cancer. 95:1483–1489.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tanaka T, Nagai Y, Miyazawa H, et al:
Reliability of the peptide nucleic acid-locked nucleic acid
polymerase chain reaction clamp-based test for epidermal growth
factor receptor mutations integrated into the clinical practice for
non-small cell lung cancers. Cancer Sci. 98:246–252. 2007.
View Article : Google Scholar
|
|
16
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
17
|
Buyse ME, Squifflet P, Laporte S, et al:
Prediction of survival benefits from progression-free survival in
patients with advanced non-small cell lung cancer: evidence from a
pooled analysis of 2,838 patients randomized in 7 trials. ASCO
Meeting Abstracts. 26(Suppl 15): abs. 8019. 2008.
|
|
18
|
Hotta K, Kiura K, Takigawa N, et al:
Progression-free survival (PFS) and overall survival (OS) in phase
III trials of systemic chemotherapy in advanced non-small cell lung
cancer (NSCLC). ASCO Meeting Abstracts. 28(Suppl 15): abs. 7624.
2010.
|
|
19
|
Malik SM, Ibrahim A, Sridhara R, et al:
Use of progression-free survival (PFS) as an endpoint in advanced
non-small cell lung cancer (NSCLC) trials: FDA perspective. ASCO
Meeting Abstracts. 28(Suppl 15): e180012010.
|
|
20
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Olaussen KA, Dunant A, Fouret P, et al:
DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Souglakos J, Boukovinas I, Taron M, et al:
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels
and clinical outcome of lung adenocarcinoma patients treated with
docetaxel/gemcitabine. Br J Cancer. 98:1710–1715. 2008. View Article : Google Scholar
|
|
23
|
Ceppi P, Volante M, Saviozzi S, et al:
Squamous cell carcinoma of the lung compared with other histotypes
shows higher messenger RNA and protein levels for thymidylate
synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar
|
|
24
|
Wu JY, Yu CJ, Yang CH, et al: First- or
second-line therapy with gefitinib produces equal survival in
non-small cell lung cancer. Am J Respir Crit Care Med. 178:847–853.
2008. View Article : Google Scholar : PubMed/NCBI
|
